« Return to News | CROs/Service Providers

Covance Q1 income above average

Friday, May 6, 2011 11:56 AM

U.S.-based drug development CRO Covance’s net revenues for the first-quarter of 2011 were $502 million, above the average analyst forecast, according to Pharma Times.

The CRO’s fourth-quarter and annual results for 2010 predicted a small increase in net revenues for the first quarter of 2011, mostly due to increased business under the company’s strategic alliance with sanofi-aventis.

Net revenues for the fourth quarter of 2010 were $491.5 million, so the $502 million for the latest quarter was in line with projections.

In the second quarter, Covance is looking for “a continued sequential increase” in net revenues and pro forma earnings per share of around $0.65.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.